The promise of genome editing: Changing bioprocessing, manufacture and much, much more
This workshop (co-sponsored by BioProNET and Horizon Discovery) brought together expert opinion leaders from academia and industry to examine the likelihood of the expectations being translated to outcomes. Via short expert presentations and focused group discussions, the participants examined how the potential of genome editing to change the manufacture of bio-based products (in terms of amount, quality, spectrum) may be enhanced and the practical consequences of such interventions from a commercial perspective.Topics covered include implications for the predictability and speed of manufacture of protein- and nucleic acid-based products and how the generation of new expression platforms may influence the design, production and downstream processing of emerging classes of bio-based products.
- Mark Fife (The Pirbright Institute)
- Claus Kristensen (GlycoDisplay Aps, Copenhagen Centre for Glycomics)
- Lorenz Mayr (GE Healthcare Life Sciences)
- Nicola McCarthy (Horizon Discovery)
- Access to the best manufacturing cell lines should not be cost prohibitive and should be designed without manufacturing handcuffs
- BioProNET is enhancing the world-leading position of the UK in the discovery, design and manufacturing of biopharmaceuticals.